| Year |
Citation |
Score |
| 2022 |
Gao Y, Volegova M, Nasholm N, Das S, Kwiatkowski N, Abraham BJ, Zhang T, Gray NS, Gustafson C, Krajewska M, George RE. Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma. Frontiers in Oncology. 11: 773186. PMID 35198433 DOI: 10.3389/fonc.2021.773186 |
0.323 |
|
| 2019 |
Bayles I, Krajewska M, Pontius WD, Saiakhova A, Morrow JJ, Bartels C, Lu J, Faber ZJ, Fedorov Y, Hong ES, Karnuta JM, Rubin B, Adams DJ, George RE, Scacheri PC. Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma. The Journal of Clinical Investigation. PMID 31498151 DOI: 10.1172/Jci127718 |
0.358 |
|
| 2019 |
Krajewska M, Dries R, Grassetti AV, Dust S, Gao Y, Huang H, Sharma B, Day DS, Kwiatkowski N, Pomaville M, Dodd O, Chipumuro E, Zhang T, Greenleaf AL, Yuan GC, et al. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nature Communications. 10: 1757. PMID 30988284 DOI: 10.1038/S41467-019-09703-Y |
0.443 |
|
| 2016 |
Krajewska M, Moore NF, Chipumuro E, Zhang T, Marco E, Hatheway C, Sharma B, Kwiatkowski N, Yuan G, Young RA, Gray NS, George RE. Abstract PR04: Targeting super-enhancer driven oncogene transcription through cyclin-dependent kinase inhibitors Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-Pr04 |
0.364 |
|
| 2015 |
Krajewska M, Fehrmann RS, de Vries EG, van Vugt MA. Regulators of homologous recombination repair as novel targets for cancer treatment. Frontiers in Genetics. 6: 96. PMID 25852742 DOI: 10.3389/fgene.2015.00096 |
0.421 |
|
| 2015 |
Fehrmann RS, Karjalainen JM, Krajewska M, Westra HJ, Maloney D, Simeonov A, Pers TH, Hirschhorn JN, Jansen RC, Schultes EA, van Haagen HH, de Vries EG, te Meerman GJ, Wijmenga C, van Vugt MA, et al. Gene expression analysis identifies global gene dosage sensitivity in cancer. Nature Genetics. 47: 115-25. PMID 25581432 DOI: 10.1038/Ng.3173 |
0.305 |
|
| 2015 |
Krajewska M, Fehrmann RS, Schoonen PM, Labib S, de Vries EG, Franke L, van Vugt MA. ATR inhibition preferentially targets homologous recombination-deficient tumor cells. Oncogene. 34: 3474-81. PMID 25174396 DOI: 10.1038/Onc.2014.276 |
0.415 |
|
| 2013 |
Heijink AM, Krajewska M, Van Vugt MATM. The DNA damage response during mitosis Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. 750: 45-55. PMID 23880065 DOI: 10.1016/J.Mrfmmm.2013.07.003 |
0.443 |
|
| 2013 |
Krajewska M, Heijink AM, Bisselink YJWM, Seinstra RI, Silljé HHW, Vries EGEd, Vugt MATMv. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination Oncogene. 32: 3001-3008. PMID 22797065 DOI: 10.1038/Onc.2012.296 |
0.488 |
|
| 2012 |
Vugt MATMV, Krajewska M, Sillje H, Heijink AM, Bisselink Y, Vries EGEd. SP-02: Cell Cycle Regulation of the DNA Damage Response: Targeting WEE1 Kinase to Impair DNA Repair. Radiotherapy and Oncology. 104: 21. DOI: 10.1016/S0167-8140(15)34556-4 |
0.457 |
|
| 2011 |
Krajewska M, Bisselink Y, Vugt MAv. Abstract 2970: Interference with DNA repair through inhibition of Wee1 Cancer Research. 71: 2970-2970. DOI: 10.1158/1538-7445.Am2011-2970 |
0.488 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2010 |
Krajewska M, Van Vugt MATM. Building a great wall around mitosis: Evolutionary conserved roles for the Greatwall/MASTL kinases in securing chromosome stability Cell Cycle. 9: 3842. PMID 20948280 DOI: 10.4161/Cc.9.19.13282 |
0.228 |
|
| 2024 |
Pomaville M, Chennakesavalu M, Wang P, Jiang Z, Sun HL, Ren P, Borchert R, Gupta V, Ye C, Ge R, Zhu Z, Brodnik M, Zhong Y, Moore K, Salwen H, ... ... Krajewska M, et al. Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation. Cell Reports. 43: 114165. PMID 38691450 DOI: 10.1016/j.celrep.2024.114165 |
0.222 |
|
| 2022 |
Sengupta S, Das S, Crespo AC, Cornel AM, Patel AG, Mahadevan NR, Campisi M, Ali AK, Sharma B, Rowe JH, Huang H, Debruyne DN, Cerda ED, Krajewska M, Dries R, et al. Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Nature Cancer. PMID 36138189 DOI: 10.1038/s43018-022-00427-5 |
0.193 |
|
| 2003 |
Kałuzny JJ, Szaflik J, Czechowicz-Janicka K, Kałuzny J, Orzalkiewicz A, Zaleska A, Krajewska M, Stewart JA, Leech JN, Stewart WC. Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. Acta Ophthalmologica Scandinavica. 81: 349-54. PMID 12859261 DOI: 10.1034/J.1600-0420.2003.00097.X |
0.168 |
|
| 2004 |
Kałuzny JJ, Szaflik J, Czechowicz-Janicka K, Kałuzny J, Orzałkiewicz A, Zaleska-Zmijewska A, Krajewska M, Stewart JA, Leech JN, Stewart WC. [Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients]. Klinika Oczna. 106: 241-2. PMID 15510513 |
0.104 |
|
| Hide low-probability matches. |